ABSTRACT Leukotriene D4 (LTD4) may be an important mediator in asthma. The effect of verapamil and sodium cromoglycate on LTD4 induced bronchoconstriction has been examined in seven patients with asthma. The bronchoconstrictor response to increasing concentrations of inhaled LTD4 (0 0032-50 jug/ml) was assessed by measuring changes in FEV1, specific airways conductance, and flow rate at 30% of vital capacity (V30(p)). Results were expressed as the provocation concentration (PC) producing a 10% fall in FEV1 (PC10FEV1), a 35% fall in specific airways conductance (PC3,sGaw), and a 30% fall in flow at 30% of vital capacity (PC30 V30(p)). Neither verapamil nor cromoglycate inhibited LTD4 induced bronchoconstriction in asthmatic subjects. These results suggest that in asthmatic patients LTD4 induced bronchoconstriction is not mediated via verapamil or cromoglycate sensitive mechanisms.
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The leukotrienes (LTs), including LTD4. may be important mediators in asthma. LTD4 is released both in vitro and in vivo after allergen challenge,1 -3 and is a potent bronchoconstrictor.45 The mechanism of LTD4 induced bronchospasm in asthma has not, however, been established. The calcium channel blocker verapamil partially inhibits the bronchoconstrictor response to LTD4 in vivo but not in vitro in non-asthmatic human bronchi,6 and only at very high concentrations in isolated trachea from the guinea pig.7 These results suggest that in guinea pigs and non-asthmatic human subjects LTD4 induced bronchoconstriction occurs as a result both of a direct effect on airway smooth muscle that is insensitive to the inhibitory action of verapamil and of an indirect effect via a verapamil sensitive mechanism. Similarly, in guinea pigs sodium cromoglycate partially inhibits the contractile response to LTD4 in vivo but not in vitro.7 Thus in this species cromoglycate appears capable of inhibiting an indirectly mediated bronchoconstrictor response of LTD4.
In this study we examined the effect of pretreatment with verapamil and sodium cromoglycate on LTD4 induced bronchoconstriction to determine Address for reprint requests: Dr J A Roberts, Department of Respiratory Medicine, Western Infirmary, Glasgow GIl 6NT. Accepted 12 May 1986 whether in asthma LTD4 induced airway narrowing depends on a mechanism sensitive to verapamil or to sodium cromoglycate or on both types of mechanism.
Methods

PATIENTS
We studied seven patients with asthma (table 1) , four of whom were women. Their ages ranged from 22 to 49 years. All were atopic and were non-smokers. All were taking inhaled ,B2 adrenoceptor agonists by pressurised aerosol, three were taking inhaled corticosteroids regularly, and two were taking sodium cromoglycate. All ,B2 agonists were discontinued 12 hours before testing and sodium cromoglycate 24 hours before testing. Inhaled corticosteroids were continued. All subjects gave informed consent and the experimental protocol was approved by the Western Infirmary ethical committee.
IN VIVO MEASUREMENTS
Airways resistance (Raw) and thoracic gas volume (TGV) were measured in a constant volume body plethysmograph (Fenyves and Gut), a computerised data collection and analysis system8 based on the method of DuBois et a19 being used. The results were expressed as specific airways conductance (sGaw) (= 1/Raw x TGV). The mean of eight measurements was taken for the sGaw value. The maximum ex-753 (fig 1) .
The geometric mean PC1OFEV1 was 0-35 pg/ml after verapamil compared with 0 47 mg/ml after the control (NS). PC35sGaw was 0-69 Mg/ml after control and 0-37 HIg/ml after verapamil (NS). Mean PC30V3O(p) was 0 41 jug/ml after the control and 0 31 pg/ml after verapamil (NS). Sample dose-response curves for 23 The pathogenesis of aspirin induced asthma is unknown but increased production of lipoxygenase products such as LTD4 may play a part. 24 Possibly sodium cromoglycate acts as a leukotriene antagonist. Our results show that sodium cromoglycate is not a specific inhibitor of LTD4 in patients with asthma. This finding confirms and extends the work of Holroyde et al,5 who showed that in normal subjects sodium cromoglycate had no effect on airway narrowing induced by LTD4
In summary, we have shown that neither verapamil nor sodium cromoglycate inhibits LTD4 induced bronchospasm in patients with asthma. This contrasts with the action of verapamil in non-asthmatic subjects. 
